Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088784 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNA7CHRNA4CHRNA5BRD4 | |
| Hydrochloric Acid SCHEMBL21801537 | 0.98 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA4CHRNA5BRD4 | |
| SCHEMBL24872393 | 0.95 | CYP1A2 (0.44) | CHRNB2CHRNA7CHRNA4CHRNA5BRD4 | |
| SCHEMBL27325877 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL13662774 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL15781609 | 0.80 | EPHX2 (0.40) | CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL336170 | 0.80 | CHRNB2 (0.45) | CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL336171 | 0.80 | CHRNB2 (0.45) | CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL6922946 | 0.80 | SMN1; SMN2 (0.45) | BRD4 | |
| SCHEMBL863635 | 0.80 | SMN1; SMN2 (0.45) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-04-18 | — | — | US | disclosed |
| US-20210009600-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-14 | — | — | US | disclosed |
| US-20210009600-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-14 | — | — | US | disclosed |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-12-08 | — | — | US | disclosed |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-12-08 | — | — | US | disclosed |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| WO-2020052631-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-03-19 | — | — | WO | disclosed |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009094457-A2 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094457-A2 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009600-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | CHRNB2 1903/4885CHRNA7 2108/4885CHRNA4 2049/4885 |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | ADORA2A, ADORA3, ADORA2B | CHRNB2 1903/4885CHRNA7 2108/4885CHRNA4 2049/4885 |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | UGT2B7, CYP3A7, CYP3A43 | CHRNB2 3462/4885CHRNA7 2834/4885CHRNA4 3927/4885 |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | ADORA2A, ADORA3, ADORA2B | CHRNB2 1903/4885CHRNA7 2108/4885CHRNA4 2049/4885 |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | CHRNB2 1903/4885CHRNA7 2108/4885CHRNA4 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.